Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.
Lars Petter
LP
Jordheim
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003842:Deoxycytidine Kinase / Q000235:genetics*; D015971:Gene Expression Regulation, Enzymologic; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000235:genetics*; D008231:Lymphopenia / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D003842:Deoxycytidine Kinase; D014740:Vidarabine; C024352:fludarabine